AZ eyes FDA verdict on Lynparza in adjuvant breast cancer in Q1The FDA will deliver a verdict on AstraZeneca’s PARP inhibitor Lynparza as an adjuvant treatment for breast cancer Share XAZ eyes FDA verdict on Lynparza in adjuvant breast cancer in Q1https://pharmaphorum.com/news/az-eyes-fda-verdict-on-lynparza-in-adjuvant-breast-cancer-in-q1/
Merck wins FDA nod for Keytruda as adjuvant kidney cancer treatmentMerck & Co has chalked up another win in drive to move PD-1 inhibitor Keytruda earlier in the Share XMerck wins FDA nod for Keytruda as adjuvant kidney cancer treatmenthttps://pharmaphorum.com/news/merck-wins-fda-nod-for-keytruda-as-adjuvant-kidney-cancer-treatment/
Roche scores adjuvant lung cancer approval for TecentriqRoche has claimed an earlier-than-expected FDA approval for its checkpoint inhibitor Tecentriq in non-small cell lung cancer (NSCLC), Share XRoche scores adjuvant lung cancer approval for Tecentriqhttps://pharmaphorum.com/news/roche-scores-early-adjuvant-lung-cancer-approval-for-tecentriq/
BMS gets FDA nod for Opdivo as first adjuvant bladder cancer therapyBristol Myers Squibb has scored a win in its drive to get Opdivo into earlier lines of cancer Share XBMS gets FDA nod for Opdivo as first adjuvant bladder cancer therapyhttps://pharmaphorum.com/news/bms-gets-fda-nod-for-opdivo-as-first-adjuvant-bladder-cancer-therapy/
FDA starts speedy review of Keytruda for adjuvant kidney cancerMerck & Co is looking at a decision from the FDA in December on its application to market Share XFDA starts speedy review of Keytruda for adjuvant kidney cancerhttps://pharmaphorum.com/news/fda-starts-speedy-review-of-keytruda-for-adjuvant-kidney-cancer/
Roche gets fast FDA review for Tecentriq in adjuvant lung cancerRoche is preparing for a December verdict from the FDA on adjuvant use of its PD-L1 inhibitor Tecentriq Share XRoche gets fast FDA review for Tecentriq in adjuvant lung cancerhttps://pharmaphorum.com/news/roche-gets-fast-fda-review-for-tecentriq-in-adjuvant-lung-cancer/
BMS claims first EU okay for adjuvant oesophageal cancer immunotherapyBristol-Myers Squibb is in a battle with Merck & Co for position in the upper gastrointestinal cancer immunotherapy Share XBMS claims first EU okay for adjuvant oesophageal cancer immunotherapyhttps://pharmaphorum.com/news/bms-claims-eu-okay-for-opdivo-in-adjuvant-oesophageal-cancer/
ASCO21: Lynparza aces adjuvant breast cancer therapy trialAstraZeneca and Merck & Co’s Lynparza is primed for even wider use in the treatment of breast cancer Share XASCO21: Lynparza aces adjuvant breast cancer therapy trialhttps://pharmaphorum.com/news/asco21-lynparza-aces-adjuvant-breast-cancer-therapy-trial/
Filing beckons as Lynparza hits the mark in adjuvant breast cancerAstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer, Share XFiling beckons as Lynparza hits the mark in adjuvant breast cancerhttps://pharmaphorum.com/news/filing-beckons-as-lynparza-hits-the-mark-in-adjuvant-breast-cancer/
